Hints and tips:
Related Topics
...Kare Schultz, Teva’s chief executive, said it was the first generic pharma company to launch a sustainability-linked bond that included targets for access to medicines....
...“We’ve made it clear that we were willing to help but it has not resulted in any agreements,” Kåre Schultz told the Financial Times about conversations with the vaccine makers whose jabs have been authorised...
...“We’ve made it clear that we were willing to help but it has not resulted in any agreements,” Kare Schultz, chief executive of Teva, told the Financial Times about conversations with pharmaceutical companies...
...“We’ve made it clear that we were willing to help but it has not resulted in any agreements,” Kåre Schultz told the Financial Times....
...Kåre Schultz, Teva’s chief executive, recently completed a two-year restructuring of the company, reducing costs and making $173m in operating income in the second quarter, up from a loss in the same period...
...Kåre Schultz, the Teva chief executive who joined to lead the turnround, said shareholders are learning that the group now keeps its promises....
...Teva chief executive Kare Schultz — who previously described the mass litigation as a “little game for a group of lawyers” — said the fundamentals of the case had not changed....
...Kåre Schultz compared the claims against Teva and others to trying to pin the blame for drunk driving on the makers of alcoholic drinks....
...Kare Schultz, Teva president and chief executive, said the mounting lawsuits addressed at opioid makers and distributors were “political” rather than a “classical legal situation”....
...Shares in Teva fell as much as 8 per cent in morning trading after Kare Schultz, chief executive, said the company faced generic competition for Copaxone, used to treat MS, and the introduction of generic...
...The settlement comes after Kåre Schultz, Teva’s chief executive, said earlier this month that the wave of lawsuits was unfair because pharmaceutical companies had followed the law....
...Kare Schultz of Lundbeck will become Teva’s fourth chief executive in a decade. If his history at the Danish group is any guide, expect big changes at the Israeli drugmaker....
...Teva has appointed Kare Schultz from Danish drugmaker Lundbeck to be its new chief executive, ending a seven month search which saw the Israeli pharmaceuticals company linked with AstraZeneca’s Pascal Soriot...
...Kåre Schultz, Teva’s recently appointed chief executive, told the Financial Times that cuts would be spread across its global operations and declined to put a figure on the number of jobs that will be lost...
...However, Kåre Schultz, Teva’s recently appointed chief executive, has told investors he wants to either raise the price of some of these “non-economical” drugs or stop manufacturing them altogether....
...Kare Schultz, who took over as chief executive in November, said the results for the fourth quarter “were as expected” but “reflect the pressure that the business has been under since 2015”....
...Teva has appointed Kåre Schultz as chief executive, ending a seven-month search that led the world’s largest maker of generic drugs to approach two industry heavyweights, including AstraZeneca’s Pascal Soriot...
...Earlier on Monday, Teva announced that it had concluded the seven month-long search for its new chief executive, appointing Kare Schultz from Danish drugmaker Lundbeck to the top slot, a move that sent the...
...The Israeli pharmaceuticals group on Monday ended a protracted seven-month search for a chief executive with the appointment of Kåre Schultz, who currently holds the same role at Lundbeck, the Danish drugmaker...
...“We are launching a comprehensive restructuring plan, crucial to restoring our financial security and stabilising our business,” said Kåre Schultz, Teva’s recently-appointed chief executive....
...Kåre Schultz, chief operating officer of Novo Nordisk, the world’s biggest maker of insulin for diabetics, says rising costs are leading to a convergence of healthcare systems, with all countries sharing...
...Kåre Schultz, chief operating officer at Novo Nordisk of Denmark, also points out that genetic differences and variations in average body mass make international comparisons of insulin prices difficult....
International Edition